Authors: Lixia Bai Rui Mao Jintao Wang Ling Ding Shiwen Jiang Chenfei Gao Huijie Kang Xiao Chen Xuesong Sun Juan Xu
Publish Date: 2015/02/03
Volume: 32, Issue: 3, Pages: 57-
Abstract
Smallmolecule inhibitors targeted MAPK have been wildly used for some cancer therapeutics as a biologically viable model but no one has been used for cervical caner ERK1/2 one of MAPK kinases is expressed high in cervical cancer tissue The aim of the present study was to evaluate the effects of ERK1/2 inhibitor U0126 on proliferation and apoptosis of cervical cancer cells and appraise the correlated mechanism of the effects In this study the cell proliferation of Hela and C33A cervical cancer cells was tested by Cell Counting Kit8 CCK8 assay and cell counting after treated with ERK1/2 inhibitor U0126 The cell cycle and apoptosis were evaluated by flow cytometry FCM The protein levels of ERK1/2 and cFos and cJun were detected by Western blot The results indicated that after downregulating ERK1/2 proteins with the inhibitor U0126 Hela and C33A cells proliferation was inhibited cell apoptosis was promoted the proportions of G0/G1 stage in cell cycle increased and G2/M stages decreased After downregulating ERK1/2 proteins of Hela and C33A cells the expression levels of p–cFos protein decreased while p–cJun protein increased The results of this study indicated that ERK1/2 may promote the development of cervical cancer cells suggesting ERK1/2 inhibitor may be used as an effective target for cervical cancer therapies working for It might inhibit cervical cancer cells growth via regulating the transcription factors expression of cFos and cJun
Keywords: